Prognostic factors for patients treated with abiraterone

Cecília M Alvim; André Mansinho; Rita S Paiva; Raquel Brás; Patrícia M Semedo; Soraia Lobo-Martins; Carolina B da Ponte; Daniela Macedo; Leonor Ribeiro; José P Dos Reis; Isabel Fernandes; Luís Costa

doi:10.2144/fsoa-2019-0079

Prognostic factors for patients treated with abiraterone

Future Sci OA. 2019 Dec 12;6(2):FSO436. doi: 10.2144/fsoa-2019-0079.

Authors

Affiliations

¹ Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, 1649-035, Portugal.
² Luís Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.
³ Urology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, 1649-035, Portugal.

Abstract

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).

Methods: Retrospective evaluation of patients with mCRPC treated with AA.

Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10-0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14-0.41; p < 0.001).

Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.

Keywords: abiraterone acetate; metastatic castration-resistant prostate cancer; prostate-specific antigen response.